A Day 14 Endpoint for Acute GVHD Clinical Trials
Authors:
Open Access
- 4 February 2024
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (4) , 421-432
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Pediatric Cancer Foundation
- National Cancer Institute (PO1CA03942)
This publication has 21 references indexed in Scilit:
- Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantLeukemia, 2020
- Acute Graft-versus-Host Disease — Biologic Process, Prevention, and TherapyNew England Journal of Medicine, 2017
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2015
- A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre studyThe Lancet Haematology, 2015
- Estimating and comparing time‐dependent areas under receiver operating characteristic curves for censored event times with competing risksStatistics in Medicine, 2013
- Graft-versus-Host Disease Treatment: Predictors of SurvivalTransplantation and Cellular Therapy, 2010
- Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint StatementTransplantation and Cellular Therapy, 2009
- Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study DesignJNCI: Journal of the National Cancer Institute, 2008
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999